CHARGE syndrome is a multiple anomaly disorder in which patients present with a variety of phenotypes, including ocular coloboma, heart defects, choanal atresia, retarded growth and development, genitourinary hypoplasia and ear abnormalities 1 . Despite 70-90% of CHARGE syndrome cases resulting from mutations in the gene CHD7, which encodes an ATP-dependent chromatin remodeller, the pathways underlying the diverse phenotypes remain poorly understood 2 . Surprisingly, our studies of a knock-in mutant mouse strain that expresses a stabilized and transcriptionally dead variant of the tumour-suppressor protein p53 (p53 25, 26, 53,54 ) 3 , along with a wild-type allele of p53 (also known as Trp53), revealed late-gestational embryonic lethality associated with a host of phenotypes that are characteristic of CHARGE syndrome, including coloboma, inner and outer ear malformations, heart outflow tract defects and craniofacial defects. We found that the p53 25,26,53,54 mutant protein stabilized and hyperactivated wildtype p53, which then inappropriately induced its target genes and triggered cell-cycle arrest or apoptosis during development. Importantly, these phenotypes were only observed with a wild-type p53 allele, as p53 25,26,53,54/2 embryos were fully viable. Furthermore, we found that CHD7 can bind to the p53 promoter, thereby negatively regulating p53 expression, and that CHD7 loss in mouse neural crest cells or samples from patients with CHARGE syndrome results in p53 activation. Strikingly, we found that p53 heterozygosity partially rescued the phenotypes in Chd7-null mouse embryos, demonstrating that p53 contributes to the phenotypes that result from CHD7 loss. Thus, inappropriate p53 activation during development can promote CHARGE phenotypes, supporting the idea that p53 has a critical role in developmental syndromes and providing important insight into the mechanisms underlying CHARGE syndrome.
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Unrestrained p53 activity induced by loss of the negative regulators MDM2 or MDM4 causes early embryonic lethality 4 . To explore the role of transcriptional activation by p53 in promoting developmental failure, we examined embryonic development in knock-in mice carrying mutations in one or both of p53's two transcriptional activation domains (p53 25, 26 and p53 25, 26, 53, 54 ; Fig. 1a and Extended Data Fig. 1 ). These mutations both disrupt the p53-MDM2 interaction-recapitulating loss of MDM2 regulation-and compromise transactivation 3 . Expression of p53 25, 26 , whose ability to transactivate most (but not all) p53 target genes is severely impaired, caused early embryonic lethality 5 (at embryonic day (E) 10.5; Extended Data Fig. 2a-c) . Surprisingly, p53 25, 26, 53 ,54/1 embryos (p53 25, 26, 53, 54 is transactivation dead) also exhibited embryonic lethality but between E13. 5 Tables 1 and 2) . Lethality associated with p53 25, 26, 53, 54 depended on the presence of a wild-type p53 allele, as p53 25, 26, 53 ,54/2 adult mice were viable (Extended Data Fig. 2b, d ). This observation is in contrast to the embryonic lethality of p53 25, 26 /2 mice, which probably results from the residual transactivation potential of p53 25, 26 on genes such as Bax 3 (Extended Data Fig. 2a, b ). Our findings underscore the importance of transactivation for the embryonic lethality induced by stabilized p53 (because p53 25,26,53,54/2 mice are viable), as well as revealing an intriguing genetic interaction between p53 25, 26, 53, 54 (which is transactivation dead) and wild-type p53 during development.
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Analysis of p53 25, 26, 53 ,54/1 embryos identified numerous genderindependent developmental phenotypes that were absent in littermate controls (Figs 1 and 2 and Extended Data Figs 3 and 4). E13.5 and older p53 25, 26, 53 ,54/1 embryos commonly displayed exencephaly, as well as craniofacial defects, including square-shaped faces, short lower jaws, cleft lip and cleft palate (Fig. 1b, c and Extended Data Fig. 4a, b ). Furthermore, p53 25, 26, 53 ,54/1 embryos displayed defects in external ear formation ( Fig. 1d ) and a spectrum of inner ear defects, ranging from mild (for example, the posterior semi-circular canal (SCC) was either truncated or fused to the common crus ( Fig. 1e )) to highly abnormal (for example, extreme inner ear bone malformation). We also observed retinal coloboma in p53 25, 26, 53 ,54/1 embryos ( Fig. 1f, g) . As a potential contributor to the craniofacial defects, we examined osteogenesis 6 and found delayed bone formation in p53 25, 26, 53 ,54/1 embryos, suggesting growth retardation (Extended Data Fig. 4c ). Notably, this constellation of phenotypes is reminiscent of those in human CHARGE syndrome. In particular, the combined presentation of coloboma and inner ear defects is characteristic of CHARGE syndrome and rarely occurs in other conditions 7 .
Given this phenotypic overlap with CHARGE syndrome, we examined whether p53 25, 26, 53 ,54/1 embryos display other CHARGE-associated characteristics [8] [9] [10] . The hearts in p53 25, 26, 53 ,54/1 embryos possessed the full complement of cell types (Extended Data Fig. 4d ) but displayed outflow tract defects (for example, persistent truncus arteriosus and double outlet right ventricle; Fig. 2a and Extended Data Fig. 4e , f) accompanied by ventricular septation defects (data not shown). The atrioventricular cushions also failed to undergo remodelling, foreshadowing potential heart valve defects ( Fig. 2b and Extended Data Fig. 4f ). Notably, outflow tract and atrioventricular septation defects are highly overrepresented in patients with CHARGE syndrome compared with individuals with isolated congenital heart disease 11 . Additionally, the kidneys and thymi in p53 25, 26, 53 ,54/1 embryos were smaller than those in controls, and the kidneys displayed branching defects ( Fig. 2c and Extended Data Fig. 4g ). These phenotypes were in contrast to the liver, which exhibited normal 25, 26, 53, 54 25, 26, 53, 54 * 53,54 * 25, 26 25, 26, 53, 54 ) Silenced p53 (p53 LSL- 25, 26, 53, 54 ) pc ac lc CC pc ac lc CC p53 25, 26, 53, 54 /+ p53 25, 26, 53, 54 /+ p53 25, 26, 53, 54 /+ p53 25, 26, 53, 54 /+ p53 25, 26, 53, 54 25, 26, 53 25, 26, 53, 54 25, 26, 53, 54 /+ d p53 25, 26, 53, 54 
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architecture and haematopoiesis (Extended Data Fig. 4h ). Evaluation for choanal atresia and external genital defects, which are features of CHARGE syndrome, was precluded by late-gestational embryonic lethality. Importantly, p53-null embryos did not display CHARGE-like phenotypes, suggesting that these phenotypes result from p53 activation [12] [13] [14] (Extended Data Fig. 5 ). Collectively, the analysis of p53 25, 26, 53 ,54/1 embryonic phenotypes revealed a strong similarity to phenotypes in patients with CHARGE syndrome ( Fig. 2d and Extended Data Fig. 4i ), including the presence of hallmarks such as coloboma, ear malformations and heart defects. Additionally, we observed exencephaly and late-gestational lethality, neither of which is commonly reported in CHARGE syndrome. However, it remains possible that fetuses with more severe phenotypes of CHARGE syndrome die in utero 15, 16 .
To understand the underlying cellular basis of the p53 25, 26, 53 ,54/1 embryonic phenotypes, we examined whether p53 induced apoptosis or cell-cycle arrest in these embryos. Analysis of the retina, which is affected in coloboma, and NCCs, which are responsible for some CHARGE phenotypes, revealed more apoptosis and less proliferation in p53 25, 26, 53 ,54/1 embryos than in littermate controls ( Fig. 2e , f and Extended Data Fig. 6a , c, d).
Similar results were observed in other tissues affected in CHARGE syndrome, including the thymus, neuroepithelium and otic vesicles (Extended Data Fig. 6b , e, f). Thus, both increased apoptosis and reduced proliferation contribute to the p53 25, 26, 53 ,54/1 embryonic phenotypes.
We next investigated the molecular mechanisms by which p53 25, 26, 53 ,54 triggers CHARGE-associated phenotypes. Mutation of p53 residues 25 and 26 inhibits MDM2 interaction, resulting in inappropriate stabilization of the p53 25, 26, 53, 54 protein, as seen in untreated p53 25, 26 ,53,54/1 and p53 25, 26 ,53,54/2 mouse embryonic fibroblasts (MEFs) compared with untreated p53 1/2 MEFs ( Fig. 3a and Extended Data Fig. 7a ). Using cotransfection and co-immunoprecipitation, we found that p53 25, 26, 53, 54 interacts with wild-type p53 ( Fig. 3b and Extended Data Fig. 7b ). Moreover, overexpressing increasing amounts of Flag-p53 25, 26, 53, 54 (lanes 2-4), but not Flag-p53 (lanes 6-8), caused haemagglutinin (HA)-p53 protein accumulation ( Fig. 3c ). Similarly, immunoblot analysis with a wild-type p53-specific antibody revealed that untreated p53 25,26,53,54/1 MEFs contained more wild-type p53 protein (lane 5) than did untreated p53 1/2 or p53 1/1 MEFs (lanes 2 and 3; Fig. 3a ). To examine the effects of increased wild-type p53 abundance, we examined p53 target gene expression in p53 25, 26, 53 ,54/1 and control MEFs. p53 25, 26, 53, 54 alone displayed no transcriptional activity, as seen in genome-wide microarray analyses 3 (Extended Data Fig. 7c ) and individual gene quantitative PCR with reverse transcription (qRT-PCR) assays comparing p53 25, 26, 53 ,54/2 and p53 2/2 MEFs (Fig. 3d ). By contrast, p53 25, 26, 53, 54 combined with wild-type p53 drove elevated expression of certain p53 target genes, including Noxa (also known as Pmaip1) and Pidd, but not p21 (also known as Cdkn1a) and Mdm2, relative to the levels in p53 1/2 and p53 1/1 MEFs, suggesting that p53 25, 26, 53, 54 activates wild-type p53 to induce the expression of specific p53 target genes ( Fig. 3d and Extended Data Fig. 7d ). Similarly, overexpression of p53 25, 26, 53, 54 , but not wild-type p53, in p53 1/1 MEFs significantly enhanced the expression of certain p53 target genes (Extended Data Fig. 7e ). Quantitative chromatin immunoprecipitation (ChIP) analyses revealed that this selective target gene activation resulted from greater binding of p53 to the response elements of particular target genes in p53 25, 26 ,53,54/1 MEFs than in p53 1/2 MEFs (Fig. 3e ). This pattern probably reflects different affinities of p53-binding sites for p53 such that p53 can only bind to, and activate 25, 26, 53, 54 /-p53 25, 26, 53, 54 25, 26, 53, 54 /-p53 +/-p53 25, 26, 53, 54 25, 26, 53, 54 Flag-p53 25, 26, 53, 54 Relative gene expression (normalized to β-actin) 25, 26, 53, 54 /+ p53 25, 26, 53, 54 HA-p53 HA-MBP Flag-p53 25, 26, 53, 54 Flag-eGFP
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Anti-Flag IP; Anti-HA 25, 26, 53, 54 interacts with and increases wild-type p53 levels and activity. a, Immunoblot for total p53 (top row) and wild-type (WT) p53 (second row) in untreated and doxorubicin (Dox)-treated MEFs of the indicated genotypes. b-Actin was used as a loading control. b, Anti-Flag immunoprecipitation (IP) and immunoblot of p53 2/2 MEFs transiently overexpressing HA-p53 and Flag-p53 or Flag-p53 25, 26, 53, 54 . The negative controls were HA-MBP and Flag-enhanced GFP (eGFP). (See also Extended Data Fig. 7b .) c, Top, Immunoblot of p53 2/2 MEFs transiently overexpressing HA-p53 and increasing amounts of Flag-p53 or Flag-p53 25, 26, 53, 54 25, 26, 53, 54 affects p53 activity.
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transcription from, lower affinity p53-binding sites (such as those in Noxa and Pidd) when sufficiently stabilized, as is the case in the presence of both p53 25, 26, 53, 54 and wild-type p53 (ref. 17 ). Collectively, these findings suggest that in p53 25, 26, 53 ,54/1 embryos, p53 25, 26, 53, 54 interacts with and stabilizes wild-type p53, probably by compromising the interaction of p53 with MDM2, causing p53 to inappropriately induce target gene expression, cell-cycle arrest and/or apoptosis, and CHARGE-like phenotypes (Fig. 3f) .
These observations suggested that p53 may respond to CHD7 deficiency and play a role in CHARGE syndrome. Analysis of Chd7 expression levels in p53 1/2 and p53 25, 26, 53 ,54/1 MEFs revealed no significant difference, suggesting that altered Chd7 levels do not underlie the CHARGE-like phenotypes in p53 25, 26, 53 ,54/1 embryos (Extended Data Fig. 8a ). We next assessed whether p53 responds to changes in CHD7 status 15, 16, 18, 19 . Indeed, p53 and certain p53 target genes were induced in Chd7-null NCCs (Fig. 4a and Extended Data Fig. 8b ). Interestingly, ChIP analyses showed that CHD7 binds to the p53 promoter in NCCs, suggesting that CHD7 negatively regulates p53 expression, providing a mechanism by which CHD7 loss might contribute to a p53 response (Fig. 4b) , although not excluding the possibility that CHD7 deficiency could also activate p53 through other mechanisms. To directly assess p53 activation in CHARGE syndrome, we analysed CHD7-mutationpositive fibroblasts from patients with CHARGE syndrome and found higher basal p53 protein levels than in controls, as well as p53 target gene induction, following mild stress (Fig. 4c, d) . Similarly, analysis of thymi showed more p53-positive thymocytes in CHD7-mutation-positive fetuses with CHARGE syndrome than in unaffected fetuses (Fig. 4e ). Thus, p53 is activated in Chd7-null NCCs and in fibroblasts and tissue from patients with CHARGE syndrome. To establish the role of p53 downstream of Chd7 loss, we tested whether Chd7-null phenotypes are rescued by p53 heterozygosity. We found that the characteristic Chd7-null phenotypes of severe developmental delay and generalized hypoplasia at E10.5 are significantly rescued on a p53 1/2 background. Specifically, heart development and somite number, an indicator of developmental stage, are rescued, while limb, forebrain and facial morphogenesis are partially rescued (Fig. 4f, g and Extended Data Fig. 8c, d) . Thus, p53 heterozygosity rescues phenotypes caused by CHD7 inactivation, although incompletely, which is consistent with the existence of both p53-dependent and p53-independent responses downstream of CHD7 loss. Collectively, these findings demonstrate that CHD7 deficiency triggers p53 activation and p53-dependent phenotypes.
Our p53 25, 26, 53 ,54/1 mouse strain provides a new model with which to study features that are relevant to CHARGE syndrome. Mouse models of CHARGE syndrome have been generated previously by using Nethyl-N-nitrosourea (ENU) mutagenesis or by targeting the Chd7 locus 20, 21 . While Chd7 2/2 mutants display embryonic lethality at approximately E10.5, Chd7 1/2 mutants are viable, exhibiting defects of the inner ear, heart, external genitalia and choanae/palate 20, 21 . In the inner ear, Chd7 1/2 mice display truncated lateral SCCs and variably truncated posterior SCCs 20, 22 , whereas p53 25, 26, 53 ,54/1 embryos primarily exhibit posterior SCC defects or defects in all three SCCs, similarly to patients with CHARGE syndrome, in which all three SCCs are often involved 23 . Interestingly, Chd7 1/2 mice have not been reported to display the CHARGE hallmarks of coloboma or cardiac outflow tract defects. Thus, the presence of extensive ear defects, heart defects and coloboma in p53 25, 26, 53 ,54/1 embryos highlights the utility of our model for recapitulating a broader form of CHARGE syndrome, potentially representing a phenotype that is intermediate in severity between Chd7 1/2 and Chd7 2/2 mutants. Interestingly, the set of phenotypes of p53 25, 26, 53 ,54/1 embryos is one set in a spectrum of mouse models whereby varying levels of p53 activity trigger different phenotypes. Unlike Mdm2 deficiency, which results in stabilized, fully active wild-type p53, the combination of wild-type p53 and p53 25, 26, 53, 54 in p53 25, 26, 53 ,54/1 embryos results in modest p53 activation, causing lethality and phenotypes less severe than Mdm2 loss 24 . The p53 25, 26, 53 ,54/1 embryonic phenotypes are also in contrast to those seen in other hyperactive p53 mouse models, including one model in which the expression of a carboxy-terminal p53 fragment causes premature ageing and another model in which reduced MDM2 expression triggers lymphopaenia and reduced body weight in adults [25] [26] [27] . In these models, the phenotypes manifested without enhanced basal p53 activity or increased p53 stabilization, respectively, potentially explaining the lack of embryonic lethality and the milder phenotypes than observed for p53 25, 26, 53 ,54/1 embryos.
Mechanistically, our observation that p53 activation is sufficient to cause CHARGE-like phenotypes in mice suggested that activated p53 could similarly promote the characteristic defects present in human CHARGE syndrome. Indeed, p53 expression and activity are increased in the presence of CHD7 deficiency, and phenotypes triggered by CHD7 loss are partially rescued by p53 heterozygosity. This finding is in contrast to a study in which p53 morpholinos failed to rescue Chd7 deficiency in zebrafish, perhaps reflecting species-specific differences 28 . p53 may also function independently of CHD7 to induce the features of CHARGE syndrome, a possibility that is relevant in the ,10-30% of CHARGE cases in which CHD7 is not mutated. p53 could become 
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activated in response to other genetic alterations found in CHARGE syndrome, or components of the p53 pathway could themselves be mutated in some CHARGE cases. Our sequencing analysis of the p53 coding region in 25 CHD7-mutation-negative patients with CHARGE failed to reveal any mutations, potentially because modest p53 activation may be difficult to achieve through point mutation, suggesting that mutations in p53 cis-regulatory regions or pathway components may be more likely. Significantly, p53 may act as a common node for developmental defects not only in CHARGE syndrome but also in other developmental syndromes, such as 22q11.2 deletion syndrome 29 . Indeed, p53 activation by ribosome dysfunction induces NCC deficiency and craniofacial defects 30 . Future studies will reveal precisely how p53 contributes to CHARGE syndrome and potentially the broader spectrum of human craniofacial and cardiac developmental syndromes.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Mouse breeding and analysis. Conditional p53 mutant mice were described previously 3, 5 . p53 LSL-mut/1 males were crossed to CMV-Cre females, and timed pregnancies were conducted 31 . Genotyping analysis was performed using yolk sac DNA. Males were identified using the PCR for the Y-chromosome-specific Zfy gene. As reported 31 , we observed mosaic Cre activity in some embryos, reflected by incomplete or no lox-Stop-lox deletion in PCR analysis of yolk sacs and in p53 immunohistochemical analysis in embryos. Embryos that showed little to no recombination of the lox-Stop-lox allele were kept separate for all analyses. In the text and figure labels, the Cre nomenclature for both control and p53 25, 26, 53 ,54/1 embryos is excluded for simplicity. The genotypes of p53 25, 26, 53 ,54/1 mice carrying a CMV-Cre transgene lack the LSL designation because the lox-Stop-lox element has been deleted from the genome. Controls in analyses comprise littermate embryos both with and without the CMV-Cre transgene (Extended Data Fig. 3 ). Mice were maintained on a mixed 129/Sv; C57BL/6J background. Chd7-deficient gene-trapped mice were described previously 21 . Controls for embryo somite number rescue analysis comprised Chd7 1/1 p53 1/1 , Chd7 1/1 p53 1/2 , Chd7 1/2 p53 1/1 and Chd7 1/2 p53 1/2 embryos. Sample sizes were estimated, based on previous embryogenesis work, to be able to reach significant conclusions. For example, using a chi-squared test, we can estimate that 24 embryos are required to obtain a significance level of 5% if all homozygous embryos were non-viable and from a heterozygous mating where homozygotes should represent 25% of the total based on Mendelian ratio. All animal work was done in accordance with the Stanford University APLAC. Embryo tissue analysis. Embryos were examined under a dissecting microscope for the presence of a heartbeat and for other abnormalities, in a blinded fashion, before genotyping, and images of either fixed or live embryos were acquired using the dissecting microscope. Whether mice were alive was determined by the presence of a heartbeat. All analyses were performed on embryos of specified ages as determined by the expected stage of tissue and organ development in control embryos. Within age groups, embryos were randomly assigned for the analysis of individual tissues. Heart, inner ear and craniofacial analyses were performed with the assistance of collaborators who were blinded to the genotypes. Histological analysis was performed on haematoxylin and eosin stained paraffin-embedded sagittal, coronal or transverse embryo sections using standard protocols. Consecutive 7-mm sections were evaluated for heart and craniofacial analyses. Whole-mount images for craniofacial analysis were created by staining embryos in 70% ethanol with ethidium bromide and imaging with ultraviolet radiation. Whole-mount cleaved caspase 3 (CC3) staining was performed as described previously 32 with anti-CC3 antibody (Cell Signaling Technology, 9664), and embryos were developed with diaminobenzidine (DAB) (Vector Labs). Immunohistochemistry and immunofluorescence were performed as described with anti-CC3 antibody, anti-5-bromodeoxyuridine (BrdU) antibody (BD Bioscience, 347580), anti-p53 antibody (Vector Labs, CM5), anti-PAX3 antibody (Iowa Developmental Studies Hybridoma Bank) and human anti-p53 antibody (Santa Cruz Biotechnology, Ab1801) on paraformaldehyde-fixed, paraffin-embedded tissue, and slides were developed with either DAB or imaged by immunofluorescence microscopy. For BrdU staining, the embryos were pulsed before dissection for 20 min with 0.1 mg BrdU per g body weight. CC3-and BrdUpositive cells were quantified and normalized to the area, number of sections or total cell number. Bone and cartilage staining were performed as described previously 33 , using Alizarin red and Alcian blue to stain bone and cartilage, respectively. Bone lengths were quantified from measurements on photomicrographs acquired at 6.33magnification. The areas of the kidney and thymus were calculated from measurements on photomicrographs acquired at 2003 magnification. Inner ear analysis using the paint-fill assay was performed as described previously 34 ; paint-filled ears were imaged in brightfield using a Leica DMRB stereoscope. All individuals with affected ears that could be scored for both ears exhibited a similar severity of the defect in both ears. Additionally, while different types of analysis precluded investigation of all phenotypes in particular embryos, defects commonly occurred in combination: for example, coloboma and inner ear defects occurred together in 57% of p53 25, 26, 53 ,54/1 embryos examined. qRT-PCR. For qRT-PCR, MEFs were cultured at subconfluency; RNA was isolated by TRIzol extraction and reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen) and random primers; and PCR was performed in triplicate using the SYBR Green system (QIAGEN and Bio-Rad) and mouse-specific primers for each gene (Supplementary Methods Table 1a ) in a 7900HT Fast Real-Time PCR machine (Applied Biosystems). The results were computed relative to a standard curve made with cDNA pooled from all samples 3 . Human fibroblasts were cultured at subconfluency in DMEM with 20% serum or 0.1% serum for 24 h before RNA isolation by TRIzol extraction, and qRT-PCR was performed as above using the SYBR Green system and human-specific primers for each gene (Supplementary Methods Table 1b ). Cell culture, western blot analysis and immunoprecipitation. MEFs were derived from E13.5 embryos. For stable overexpressing MEF lines, wild-type and p53-null MEFs were transduced with pWZL-based retroviruses expressing Flag-p53, Flag-p53 25, 26, 53, 54 or empty vector as described previously 5 . Mutant p53 constructs were made via site-directed mutagenesis to bear Leu25Gln, Trp26Ser, Phe53Gln and Phe54Ser mutations, which were found to incapacitate p53's transactivation capability. In summary, a p53 cDNA, generated from MEF RNA, was amplified and engineered with AscI and PacI restriction enzyme sites using primers against the second amino acid through the stop codon (59-TTAGGCGCGCCACTGCCATGG AGGAGTC-39 and 59-GGCGTTAATTAATCAGTCTGAGTCAGGCCCCAC-39). The amplified DNA was subcloned into a pBluescript construct with the multiple cloning site replaced with AscI and PacI sites. The p53 cDNA underwent sitedirected mutagenesis (TTATGG to CAATCG and TTTTTT to CAGTCT) to generate the four mutations. The mutated p53 cDNA was confirmed by sequencing and subcloned into the appropriate expression vectors (pWZL or pcDNA) that contained three copies of either the HA or Flag tag at the amino terminus, as well as AscI and PacI sites instead of the multiple cloning sites. For western blot analysis, cells were left untreated, treated with 0.2 mg ml 21 doxorubicin (Dox) for 8 h or transfected using X-tremeGENE HP (Roche) for 24 h with pcDNA constructs (Flag-p53, Flag-p53 25, 26, 53, 54 , HA-p53 or empty vector). Cells were collected and lysed using RIPA buffer. Western blots were probed with anti-p53 (Vector Labs, CM5, 1:500), anti-wild-type p53 (provided by D. Lane and B. Vojtesek, pAB242) 35 , anti-Flag (Sigma, F3165, 1:1,000), anti-HA (Sigma, H6908, 1:1,000) and anti-actin (Sigma, A2228, 1:30,000) antibodies. Immunoprecipitation was performed on MEFs transfected with pcDNA constructs (Flag-p53, Flag-p53 25, 26, 53, 54 , HA-p53, Flag-eGFP or HA-MBP) using M2 anti-Flag agarose beads (Sigma, A2220). Dox-treated p53 1/2 (Fig. 3a, lane 6 ) and p53 25,26,53,54/2 (Fig. 3a, lane 4) MEFs controlled for wild-type p53-specific antibody activity and specificity, respectively. Cells were lysed using RIPA buffer; lysates were added to anti-Flag beads to allow the binding of Flag protein; and bound protein was retrieved by the addition of sample buffer and the centrifugation of beads. Ten per cent input was used for western blot analysis. Human fibroblasts were grown in DMEM with 20% serum, and were lysed using RIPA buffer or were incubated in 0.1% serum for 24 h before collection for RNA analysis. Western blots were probed with anti-p53 antibody (Santa Cruz Biotechnology, DO-1). The differentiation of mouse Chd7 1/1 and Chd7 2/2 (whi/whi) embryonic stem cells into NCCs was performed using an adaptation of a previously described protocol 18, 19 that has been further characterized 36 . Importantly, loss of CHD7 function does not affect the induction of NCCs, allowing for generation of the cells for this analysis 18 . Validation of NCC phenotype was performed by assessing the gene expression of the NCC markers Wnt1, Snai1 and Pax3 (Supplementary Methods Table 1a ). ChIP. Analysis of p53 binding was performed on MEFs of different genotypes. For ChIP, 30-40 3 10 7 cells were collected, and immunoprecipitation was conducted using anti-p53 antibody (Vector Labs, CM5), as previously described 37 . In brief, the cells were crosslinked following trypsinization with 1% formaldehyde and quenched with glycine. Chromatin was sheared using a Bioruptor sonicator (Diagenode), then immunoprecipitated with anti-p53-Dynabeads overnight. Immunoprecipitated DNA was washed, reverse-crosslinked and isolated using a PCR clean-up kit (QIAGEN). Immunoprecipitated DNA was analysed using qRT-PCR with binding-site-specific primers ( Supplementary Methods Table 2 ) and normalized to input. Analysis of p53 binding-site affinities was based on previously reported ChIP-sequencing data and a p53 binding-site algorithm 17, 37 . Analysis of CHD7 binding was performed using anti-CHD7 antibody on NCC-like cells differentiated from wild-type or Chd7-null (whi/whi) embryonic stem cells using the same protocol as above 18 . Human samples. All human work was conducted under human subject protocols approved by the Stanford Institutional Review Board (IRB), the University of Michigan UM-IRBMED and the Ethical Committee of d'Ile de France II (Nu 2009-164). Informed consent was obtained from participants in the study. Human fibroblasts were obtained by skin biopsy under local anaesthesia from CHARGE patients with CHD7 mutations and unaffected individuals. Thymi were obtained from pregnancies terminated for severe malformations, in accordance with French law, after genetic counselling, between 24 and 37 weeks of gestation. Detailed clinicopathological examination allowed the diagnosis of CHARGE syndrome, which was confirmed by CHD7 molecular analysis that identified a de novo nonsense mutation in each sample. Age-matched control thymi were obtained from fetuses with isolated brain malformations.
TP53 (p53) exome sequence was analysed in a group of 25 CHD7-mutationnegative patients with features of CHARGE syndrome, who were selected in the cohort based on the availability of parental DNA for segregation analysis, in case a variant was found. All TP53 coding exons were analysed by direct sequencing of PCR products comprising the ten coding exons and the adjacent intronic junctions of TP53 isoform 2 (exons 2 to 11, reference sequence NM_001126112.2) and the alternatively spliced exon 10 of isoforms 3 and 4 (reference sequences NM_001126114.2 and NM_001126113.2). This analysis failed to reveal any mutations within the coding LETTER RESEARCH region (that is, no sequence changes apart from already known single nucleotide polymorphisms). Statistical analysis. The statistical tests used were Student's t-test (equal variance), Welch's t-test (unequal variance), the Mann-Whitney test (non-parametric test) and the binomial distribution test. Owing to the presence of embryos with little or no recombination of the lox-Stop-lox allele, binomial distribution analysis was used to exclude these embryos and to determine the statistical significance for the viability of p53 25, 26, 53 ,54/1 embryos at each embryonic time point. Additional statistical analyses, with the assistance of the Stanford Biostatistics Core, were performed to assess viability over multiple embryonic time points of CMV-Cre; p53 25, 26, 53 ,54/1 embryos that had recombined versus those that had not recombined, as scored by PCR analysis (Extended Data Table 2 ).
The number of dead p53 25, 26, 53 ,54/1 embryos, as a proportion of the total (dead plus alive), was also analysed using logistic regression, with a factor for genotype and a factor for gestational age. Because some of the totals were small, we assessed significance using a permutation test, comparing the observed phenotype (the ratio of dead embryos) to a set of 10,000 random permutations of the phenotype (keeping the number of dead embryos and the total numbers unchanged at each time point and re-fitting the logistic regression). Note that this analysis assumes the effect of clustering within dams is negligible. The P value for the permutation test was 0.0234: 234 out of 10,000 random permutations showed a greater frequency of death in absolute value than the frequency of death observed for p53 25, 26, 53 ,54/1 embryos; the P value from logistic regression software was P 5 0.0003. A model allowing a continuous effect of gestational age was also fitted to explore whether the genotype affected the rate of change in the hazard of death: the slopes over time for p53 25, 26, 53 ,54/1 and control embryos were significantly different (P 5 0.0245), despite the confidence intervals at each individual time point being wide and overlapping. 31. Schwenk, F., Baron, U. & Rajewsky, K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 23, 5080-5081 (1995 
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